Live feed07:00:00·45dPRReleaseENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancerAZN· AstraZeneca PLCHealth CareOriginal source
